RemeGen and Vor score again with telitacicept, this time in IgA nephropathy
27th August 2025 Uncategorised 0China biotech RemeGen and its new U.S. partner Vor Bio are on a roll with their first-in-class autoimmune treatment telitacicept. Two weeks after revealing the success of a phase 3 trial of telitacicept in Sjögren’s disease, the companies have reported another late-stage win for the injected treatment.
More: RemeGen and Vor score again with telitacicept, this time in IgA nephropathy
Source: fierce